Madan R - Search Results

1

Lutetium-177-PSMA-617: A Vision of the Future.

Chandran E, Figg WD, Madan R. Chandran E, et al. Among authors: madan r. Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985. Cancer Biol Ther. 2022. PMID: 35220877 Free PMC article.

2

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

Madan RA, Mohebtash M, Schlom J, Gulley JL. Madan RA, et al. Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi: 10.1517/14712590903321421. Expert Opin Biol Ther. 2010. PMID: 19857185 Free PMC article.

3

Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.

Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL. Zhu W, et al. Am J Ther. 2010 Mar-Apr;17(2):176-81. doi: 10.1097/MJT.0b013e3181c6c0b2. Am J Ther. 2010. PMID: 20019584 Free PMC article. Review.

4

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Ning YM, et al. J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308663 Free PMC article. Clinical Trial.

5

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Stein WD, et al. Clin Cancer Res. 2011 Feb 15;17(4):907-17. doi: 10.1158/1078-0432.CCR-10-1762. Epub 2010 Nov 24. Clin Cancer Res. 2011. PMID: 21106727 Free PMC article.

6

Overcoming chemotherapy resistance in prostate cancer.

Madan RA, Pal SK, Sartor O, Dahut WL. Madan RA, et al. Clin Cancer Res. 2011 Jun 15;17(12):3892-902. doi: 10.1158/1078-0432.CCR-10-2654. Clin Cancer Res. 2011. PMID: 21680545 Free PMC article.

7

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Dahut WL, et al. BJU Int. 2013 Jun;111(8):1269-80. doi: 10.1111/j.1464-410X.2012.11667.x. Epub 2013 Feb 18. BJU Int. 2013. PMID: 23419134 Free PMC article. Clinical Trial.

8

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL. Figg WD, et al. Among authors: madan ra. Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17. Clin Genitourin Cancer. 2013. PMID: 23684781 Free PMC article. Clinical Trial.

9

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL. Karzai FH, et al. BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8. BJU Int. 2015. PMID: 25407442 Free PMC article. Clinical Trial.

10

Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.

Karzai FH, Madan RA, Figg WD. Karzai FH, et al. South Med J. 2015 Apr;108(4):224-8. doi: 10.14423/SMJ.0000000000000266. South Med J. 2015. PMID: 25871992 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

677 results

Search Page